3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Locally Advanced Thyroid Gland Carcinoma
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
Cetuximab
14
Cisplatin
12
pembrolizumab
11
Paclitaxel
9
Gemcitabine
9
durvalumab
6
Nivolumab
6
Docetaxel
6
toripalimab
5
Carboplatin
5
Radiotherapy
4
Fluorouracil
4
Cyclophosphamide
4
fludarabine
3
Valproic Acid
3
Capecitabine
3
tremelimumab
2
spartalizumab
2
nimotuzumab
2
irinotecan sucrosofate
2
fludarabine phosphate
2
cemiplimab
2
anlotinib
2
Sunitinib
2
S 1 (combination)
2
Radiation
2
Oxaliplatin
2
NVP-BKM120
2
Methotrexate
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
entrectinib
×
Head & Neck
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA